1. Background {#Section1}
=============

Bladder cancer is the sixth most common disease in men and the seventeenth most common in women [@B1]. Its incidence ranks first among malignant cancers of the urinary system and second only to prostate cancer in Western countries. The pathologic histology shows that more than 90% bladder cancer patients have bladder transitional cell carcinoma, 5% have bladder squamous cell carcinoma, and less than 2% have bladder adenocarcinoma [@B2]. Moreover, the incidence of bladder cancer is three to four times higher in men than in women [@B3], [@B4]. Among patients who receive an initial diagnosis of bladder cancer, 70% to 85% have non-muscle-invasive bladder cancer (NMIBC) and 15% to 30% have muscle-invasive bladder cancer (MIBC) [@B5]. NMIBC is known as superficial bladder cancer; its pathological stages include Ta (papillary), T1 (infiltration lamina propria), and carcinoma in situ. Ta patients comprise 70% of cases, T1 roughly 20% and carcinoma in situ about 10%. MIBC is known as invasive bladder cancer; its pathological stages include T2, T3 and T4 [@B5], [@B6]. Up to 80% of NMIBC patients relapse within 5 years; 30% of Ta patients progress to MIBC; while those with T1 and carcinoma in situ are more likely to develop MIBC [@B7], [@B8]. Transurethral resection is seen as a standard curative treatment for NMIBC, whilst radical cystectomy plus neoadjuvant chemotherapy is used to treat MIBC [@B5], [@B9].

The pathogenesis of bladder cancer is complex and multifactorial due to either intrinsic genetic factors or external environmental factors. Two major confirmed factors are smoking and prolonged exposure to aromatic amines. Smoking is the most confirmed pathogenic factor, as about 30% to 50% of bladder cancers can be ascribed to smoking, which can amplify the incidence of bladder cancer by two to four times. The incidence rate is in proportion to the intensity and duration of smoking. Haematuria is the earliest and most common symptom of primary bladder cancer. The nature of haematuria includes full-course, intermittent and painless gross haematuria, sometimes accompanied by blood clots [@B8], [@B10]. Other clinical manifestations at the initial diagnosis include microscopic haematuria, lower urinary tract symptoms and urinary tract infection [@B11]. Statistics show that bladder cancer has high incidence, progression and recurrence rates. Therefore, in clinical work it is extremely important to accurately diagnose and assess patients with early bladder cancer and especially to monitor high-risk postoperative bladder cancer patients. The most common ways to diagnose bladder cancer include cystoscopy and biopsy, imaging methods, urinary cytology, fluorescence in situ hybridization, and urine protein detection (BTA-STAT, BTA-TRAK, NMP22 and ACCU-DX) [@B8], [@B12]. Urinary cytology and cystoscopy/biopsy are the current gold standard examination tools to diagnose bladder cancer. However, cystoscopy is an invasive examination and can cause pain, bleeding, urinary tract infections and other complications. In addition, it is sometimes difficult for cystoscopy to detect tumours in secluded corners of the bladder, which constrains its clinical application. Cytology is a non-invasive test that can directly identify tumour cells shed in the urine. It is simple to use and inexpensive and performs well, although it has low sensitivity and low diagnostic efficiency, especially with low-grade bladder cancer.

2. Materials and Methods {#Section2}
========================

This study used the keyword information retrieval method. References related to bladder cancer detection were collected, summarized and organized to select representative and reliable research articles that matched the study\'s requirements. PubMed and Medline complete were used for systematic retrieval from 2008 to 2018. First, we set two keywords (\'bladder cancer\' and \'detection\') for abstract retrieval, resulting in 2783 relevant English-language papers. Second, 297 full texts met the inclusion criteria by including the results of detection of bladder cancer with or without a clinical trial. We then used \'bladder cancer, detection\' as abstracts and \'clinical trial, accuracy\' as full articles that had been reviewed. After all exclusions, 44 relevant articles were obtained. The main exclusion criterion was that the tests had not been used for clinical diagnosis. Other publications regarding urinary problems and other cancers were also excluded. The flowchart for the entire article search is presented in Figure [1](#F1){ref-type="fig"}.

All diagnostic methods for clinical use have their own pros and cons; therefore, it becomes a top priority to find a method of detection and diagnosis of bladder cancer that is characterized by high sensitivity, high specificity, low cost, non-invasive nature, ease of use and good reproducibility. Sensitivity and specificity are both widely used to portray the results of diagnoses in the medical diagnosis field. Specificity examines healthy subjects who show negative results, and sensitivity examines those with cancer who show true positive results. Therefore, the use of sensitivity and specificity to compare several diagnostic methods can provide more reference information for the patients. In this study, we compared the diagnostic accuracy of various methods, so any article without information regarding such measures was excluded. In the end, we used 21 articles from PubMed and 23 articles from Medline complete for analysis.

3. Results and Discussion {#Section3}
=========================

This section summarizes the bladder cancer detection methods, their sensitivities and specificities and their advantages and disadvantages.

3.1 Urine microscopy {#Section3.1}
--------------------

Urine microscopy serves as a crucial tool to determine several conditions that can affect the kidneys and the urinary tract. Nephrologists and pathologists are both responsible for microscopic examination of urine [@B13]. Urine samples should be acquired for microscopy in the relevant examining centre using an aseptic method. Patients have no risk of injury or bacterial infection (unless urine is collected via catheterization). However, this method also has some disadvantages. The sample may include debris such as bacteria and exudates from the lower urinary tract or genital tract. If there is an increase in bacteria in the urine, it is necessary to properly identify whether its origin is urethral pollution or urinary tract infection. Catheterization performed to collect urine may also induce trauma to the urinary tract [@B14]. Table [1](#T1){ref-type="table"} shows a review of the sensitivity and specificity of urine microscopy.

3.2 Urine cytology {#Section3.2}
------------------

Urinary cytology is performed under a microscope to screen the urine of a patient with bladder cancer for cancer cells. If the sample includes abnormal cells, the doctor will ask the patient for another sample. Table [2](#T2){ref-type="table"} shows a review of the sensitivity and specificity of urine cytology. Based on the review, Table [3](#T3){ref-type="table"} shows the advantages and disadvantages of the detection method.

3.3 Urine markers {#Section3.3}
-----------------

Urine markers are a combined method for bladder cancer diagnosis. Although more than 30 urinary biomarkers are recognized to diagnose bladder disease, only a few can be used [@B23]. It is universally acknowledged that bladder cancer should be diagnosed with urine tests such as the UroVysion test, ImmunoCyt test or NMP-22 test. Each of these examinations is conducted by recognizing chemicals, proteins and changes in chromosomes in the urine [@B24]. Commercially available tests include:Urine cytologyFluorescence in situ hybridization (FISH)Nuclear matrix protein (NMP-22)BTA *stat*BTA TRAKImmunoCyt/uCyt+CertNDxCxBladder

When surveying a marker\'s operation, researchers should consider the research population because it could have an influence on the operation of a marker at a later stage of the illness. Although the mark of the machine may be low, several markers have been subjected to focused research. Based on the review of urine markers and their sensitivity and specificity given in Table [4](#T4){ref-type="table"}, it can be seen that the advantages of this method include its high sensitivity, greater number of choices, less pain and detection of low-grade tumours. In contrast, its disadvantages mainly include its high cost, invasive nature, complexity and high inter-observer variability [@B25].

3.4 Cystoscopy {#Section3.4}
--------------

This is the most vital test for diagnosing bladder cancer using cystoscope. Patients can undergo this test under local anaesthesia or general sedation. If tissue sampling is required, cystoscopy must take place under general anaesthesia [@B34]. Based on the review of the method and its sensitivity and specificity in Table [5](#T5){ref-type="table"}, it can be seen that one advantage is that it is easily performed [@B35]. Every alternative method should be examined and evaluated with the doctor, who can confirm which choice will work best for the patients. However, this method has disadvantages; it might miss a small flat tumour, and it involves instrumentation and thus a risk of urethral injury, urinary tract infection and haematuria [@B36].

3.5 CT {#Section3.5}
------

A computed tomography (CT) is not used for screening but is used for staging once bladder cancer is diagnosed via cystoscopy and biopsy or via transurethral resection. A CT urogram is an imaging test to examine the urethra system that uses X- rays to generate multiple images of a part of a subject\'s body (e.g., blood vessels, soft tissue); these images are then sent to a computer for reconstruction of detailed three-dimensional images [@B41]. The advantages of this method include: (1) it completely eliminates the superimposition of images of structures outside the area of interest; and (2) the statistics gained from one CT image, which comprises multiple contiguous or one helical scan, are considered images in the axial, coronal or sagittal planes, relying on the diagnostic task, which is seen as multi-planar reformatted imaging. The disadvantages of this method include: (1) a slight increase in the risk of cancer in later life via exposure to ionizing radiation (X-rays); (2) its use of higher doses of radiation than normal X-ray scanning makes the risks (while still small) greater than other types in general; and (3) injection of a contrast medium (dye) can lead to kidney insult or allergic reaction [@B42]. Table [6](#T6){ref-type="table"} shows a review of the CT scan method and its sensitivity and specificity.

3.6 MR imaging {#Section3.6}
--------------

Bladder cancer is staged mainly with magnetic resonance imaging (MRI), a form of tomography that uses a powerful magnetic resonance phenomenon to extract electromagnetic signals from the body and reconstruct body information [@B47]. Before starting the MRI scan, it is essential that any metal articles (e.g., watches, jewellery, piercings, etc.) be removed from the subject\'s body because metal can affect the image quality and hence alter the diagnosis [@B47]. Because no radiation process is involved in MRI, it presents no danger to individuals who are required to avoid radiation, such as pregnant women or children, and it is easy to perform. Scanning is carried out in an enclosed space, so individuals who are claustrophobic or are otherwise unable or unwilling to remain in an enclosed space may have trouble undergoing MRI. MRI scanners often makes significant noises and require large amounts of electric current, and their cost is usually high [@B48]. Table [7](#T7){ref-type="table"} shows a review of the MRI method and its sensitivity and specificity.

3.7 Combined method - Urine Markers and Urine Cytology {#Section3.7}
------------------------------------------------------

A combined method diagnosis system combines one or more methods. This combination will increase the accuracy of detecting cancer or other problems in the human body. The combined use of urine markers and urine cytology can improve bladder cancer detection. Table [8](#T8){ref-type="table"} compares the sensitivity and specificity of various combined urine markers and urine cytology methods.

All in all, for the selection of the bladder tumour marker to be economically affordable, the medical equipment must check the bladder pathological area completely [@B58]. Screening and examination methods that are powerful and specific should be made immediately and completely available to doctors. However, urine cytology is sometimes affected by lower efficiency with voided quality grades [@B39].

4. Conclusion {#Section4}
=============

The methods considered in this study clearly have their respective strengths. The sensitivity and specificity data in the articles were collected from various patients. We can understand the higher detection performance with the methods used. The best accuracy can also be compared between the single and combined methods. Table [9](#T9){ref-type="table"} shows the methods and the percentage range of sensitivity and specificity for each method. It can be concluded that the methods for detecting bladder cancer can be used with different modes of varying characteristics. Some of the methods are highly accurate but some are not. Nevertheless, each method has its own advantages and disadvantages.

Table [9](#T9){ref-type="table"} shows that urine makers and cystoscopy have the same highest sensitivity and the highest specificity of 97.2% and 97%, respectively. The table also shows that of the combined methods, the highest sensitivity of 94% and the highest specificity of 90% are found in urine markers and urine cytology. Bladder growth is caused by a combination of cancer-causing agents and might have a variable history. Although superficial bladder tumours occur more often, they have a tendency to progress. Each examination should ensure proper diagnosis, arrangement and evaluation.
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Paper Context
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###### 

Sensitivity and specificity of urine microscopy for bladder cancer

  Authors           Year   Sensitivity/specificity (%)   References
  ----------------- ------ ----------------------------- ------------
  Nataraju et al.   2018   87 / 92                       [@B15]
  Becker et al.     2016   87.5 / NA                     [@B16]
  Williams et al.   2010   91 / 96                       [@B17]

###### 

Sensitivity and specificity of urine cytology for bladder cancer

  Authors        Year   Sensitivity/specificity (%)   References
  -------------- ------ ----------------------------- ------------
  Kumar et al.   2017   13.3 / 100                    [@B18]
  Lee et al.     2015   86 / 73                       [@B19]
  Anai et al.    2014   83 / NA                       [@B20]
  Hajdinjak      2008   42 / 96                       [@B21]

###### 

Advantages and disadvantages of urine cytology [@B22]

  -------------------------------------------------------------------------------------------
  Specimen Type         Advantages                    Disadvantages
  --------------------- ----------------------------- ---------------------------------------
  Voided urine          Non-invasive\                 Low cellularity\
                        No instrumentation artifact   Vaginal contamination\
                                                      Poor preservation

  Catheterized          High cellularity              Invasive\
                                                      Instrumentation artifact\
                                                      Poor preservation

  Bladder washing       High cellularity\             Invasive\
                        Good cell preservation        Instrumentation artifact

  Upper tract washing   High cellularity\             Invasive\
                        Good preservation\            Instrumentation artifact
                        Selective sampling            

  Brush cytology        Selective sampling            Invasive\
                                                      Air drying possible (if direct smear)
  -------------------------------------------------------------------------------------------

###### 

Sensitivity and specificity of urine markers for bladder cancer

  Urine markers       Sensitivity/specificity (%)   References
  ------------------- ----------------------------- ----------------
  BTA TRAK            72-99 / 12.1-78               [@B26]-[@B28]
  BTA stat            56-83 / 72-85.7               [@B27], [@B29]
  NMP22               51-100 / 73-90                [@B27], [@B28]
  UroVysion           80-86 / 61-86                 [@B21], [@B30]
  ImmunoCyt           68.1-72.5 / 65.7-72.3         [@B31], [@B32]
  UBC                 53.8 / 97.2                   [@B26]
  TMPRSS2:ERGFusion   45.4 / 34.8                   [@B33]

Abbreviation: UBC=urinary bladder cancer antigen

###### 

Sensitivity and specificity of cystoscopy for bladder cancer

  --------------------------------------------------------------------------------------------
  Authors            Year   Method                  Sensitivity/specificity (%)   References
  ------------------ ------ ----------------------- ----------------------------- ------------
  Ciudin et al.      2015   Air cystoscopy          88 / 97                       [@B36]

  Horstmann et al.   2014   PDD cystoscopy          92 / 57                       [@B37]

  Shen et al.        2012   NBI or WLI cystoscopy   87.8 / 77.1 (NBI)\            [@B38]
                                                    68.3 / 82.9 (WLI)             

  van Rhijn et al.   2009   Urethra-cystoscopy      75 / 83                       [@B39]

  Allam et al.       2009   Cystoscopy              100 / 94.4                    [@B40]
  --------------------------------------------------------------------------------------------

Abbreviation: PDD=photodynamic diagnosis; NBI=narrow band imaging; WLI=white light imaging

###### 

Sensitivity and specificity of CT scan for bladder cancer

  -------------------------------------------------------------------------------------------------
  Authors           Year   Method                        Sensitivity/specificity (%)   References
  ----------------- ------ ----------------------------- ----------------------------- ------------
  Lu et al.         2012   CT for staging or restaging   82 /89                        [@B43]

  Harkirat et al.   2010   CT for restaging\             53.8 / 77.8\                  [@B44]
                           CT for restaging              86.7 / 100                    

  Swinnen et al.    2010   CT for staging\               46 / 97\                      [@B45]
                           CT for staging                46 / 92                       

  Sadow et al.      2008   CT for detection              79 /94                        [@B46]
  -------------------------------------------------------------------------------------------------

###### 

Sensitivity and specificity of MRI for bladder cancer

  Authors             Year   Method                Sensitivity/ specificity (%)   References
  ------------------- ------ --------------------- ------------------------------ ------------
  Lee M et al.        2017   MRI for staging       80.8 / 77.8                    [@B49]
  Daneshmand et al.   2012   DGE-MRI for staging   87.5 / 91.5                    [@B50]
  Rajesh et al.       2011   MRI for staging       78.2 / 93.3                    [@B51]
  Watanabe et al.     2009   MRI for staging       70 / 79                        [@B52]

Abbreviation: DGE=dynamic glucose-enhanced

###### 

Sensitivity and Specificity of urinary markers combined urine cytology

  Method                      Sensitivity/ Specificity (%)   References
  --------------------------- ------------------------------ ------------------------
  NMP 22 + Cytology           73-94 / 84-90                  [@B53], [@B54]
  BTA Stat + Cytology         91-93 / 78-90                  [@B53], [@B54]
  BTA TRAK + Cytology         68-72 / 53-75                  [@B53], [@B55]
  FDP + Cytology              68-89 / 50-78                  [@B53], [@B56]
  ImmunoCyt + Cytology        72.8-90 / 64.4-78              [@B31], [@B32], [@B54]
  UroVysion FISH + Cytology   61.9-72 / 83-89.7              [@B21], [@B57]

Abbreviation: FDP=fibrinogen degradation products

###### 

The percentage range of sensitivity and specificity in different detection methods

  Methods                          Sensitivity/Specificity (%)
  -------------------------------- -----------------------------
  Urine microscopy                 87-91 / 92-96
  Urine cytology                   13.3-86 / 73-100
  Urine markers                    45.4-100 / 12.1-97.2
  Cystoscopy                       68.3-100 / 57-97
  CT                               46-86.7 / 77.8-100
  MRI                              78.2-87.5 / 77.8-93.3
  Urine Markers + Urine Cytology   61.9-94 / 50-90
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